- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07562217
Load Incorporating Cardiac Assessment by Echocardiography In Patients With SEpsis (LIAISE Study) (LIAISE)
Load Incorporating Cardiac Assessment by Echocardiography In Patients With SEpsis: a Prospective Observational Study (LIAISE Study)
Visão geral do estudo
Status
Condições
Descrição detalhada
Background Sepsis is a global killer, whereby an infection spreads throughout the body via the bloodstream. It often leads to lethal heart damage, "septic cardiomyopathy", with mortality rates for those affected soaring above 40%. To facilitate early and appropriate intervention for damaged hearts and improve their outcomes, accurate assessment of heart function, and proper prediction of their adverse events are crucial. However, conventional cardiac assessments cannot capture heart dysfunction accurately since they have a significant limitation called "load-dependency", which means these parameters' values are affected by loading conditions on the heart, such as blood pressure and circulating blood volume. In sepsis, as these loads on the heart dramatically change minute by minute, the values of cardiac assessment also fluctuate and frequently underestimates heart damage, failing to properly predict their adverse events. To address this, novel load-incorporating echocardiographic parameters can capture heart function more accurately regardless of these hemodynamic conditions, and previous data has demonstrated its better predictive value in cardiogenic shock cases where loading conditions similarly fluctuate. As a next step, this study seeks to elucidate their utility in patients with sepsis.
Aims
- To investigate if novel load-incorporating echocardiography can predict adverse events more accurately than conventional parameters in adult patients with sepsis presenting to intensive care units (ICUs).
- To identify the most sensitive cardiac parameter to predict adverse events in sepsis, from comprehensively collected cardiac parameters along with novel-incorporating echocardiography.
Hypothesis Load-incorporating echocardiographic parameters will be more accurate in predicting the incidence of adverse events within 30 days after ICU admission than conventional echocardiographic parameters.
Outcomes Primary outcome The incidence of all-cause death for 30 days after ICU admission
Secondary outcomes
- Incidence of and time to all-cause death or cardiovascular readmission for 1 year after ICU admission
- Incidence and duration of mechanical circulatory support, mechanical ventilation, renal replacement therapy, and vasoactive agent therapy during initial admission.
- Reversibility of cardiac function (LVEF increases ≥ 5% in echo 3-5 days after ICU admission)
- Sequential Organ Failure Assessment (SOFA) score at 3 days after ICU admission
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Hideaki Nonaka, Dr
- Número de telefone: +61 449967910
- E-mail: hideaki54nonaka@gmail.com
Estude backup de contato
- Nome: Nonaka
Locais de estudo
-
-
Queensland
-
Chermside, Queensland, Austrália, 4032
- The Prince Charles Hospital
-
Contato:
- Hideaki Nonaka, Dr
- Número de telefone: +61 449967910
- E-mail: hideaki54nonaka@gmail.com
-
Contato:
- Nonaka
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Adults ≥ 18 years old.
- Clinically suspected of defined sepsis
- Sepsis-induced hypotension or hypoperfusion (arterial or venous blood lactate ≥2.0 mmol/L OR mean artery pressure ≤65 mmHg over 30 mins OR at least one vasoactive or inotropic agent administered).
- At least one dose of an IV antimicrobial has been commenced.
Exclusion Criteria:
- Suspected or confirmed pregnancy.
- Any severe concomitant diseases with limited life expectancy <30 days.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
|---|
|
Sepsis with hypotension or signs of hypoperfusion admitted to ICU
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
All cause death
Prazo: Day 30 after ICU admission
|
Day 30 after ICU admission
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
All cause death and adverse cardiac event readmission
Prazo: 1 year after ICU admission
|
Incidence of and time to all-cause death or adverse cardiac event readmissions for 1 year after ICU admission
|
1 year after ICU admission
|
|
Mechanical circulartory suport, mechanical ventilation, renal replacement therapy, and vasoactive/inotropic agent therapy
Prazo: during the initial index admission, between Day 0 and Day 30
|
Incidence and duration (days) of mechanical circulatory support, mechanical ventilation, renal replacement therapy, and vasoactive agent therapy during initial admission
|
during the initial index admission, between Day 0 and Day 30
|
|
Reversibility of cardiac function
Prazo: Day 3 to Day 5
|
Left ventricular ejection fraction increases ≥ 5% in echo from 3-5 days after ICU admission
|
Day 3 to Day 5
|
|
Sequential Organ Failure Assessment score at 3 days after ICU admission
Prazo: at Day 3 of ICU admission
|
Sequential Organ Failure Assessment score at Day 3 of index ICU admission will be assessed on a scale from 0 to 24, with higher scores indicating more severe organ failure.
|
at Day 3 of ICU admission
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
lengh of hosiptal or ICU stay
Prazo: during the initial index admission, between Day 0 and Day 30
|
during the initial index admission, between Day 0 and Day 30
|
|
|
In-hospital mortariy
Prazo: during the initial index admission, between Day 0 and Day 30
|
during the initial index admission, between Day 0 and Day 30
|
|
|
Vasoactive-inotropic score at 24, and 48 hours
Prazo: at 24 hour and 48 hour of index ICU admission
|
at 24 hour and 48 hour of index ICU admission
|
|
|
Amount of fluid administered for the first 24 hours in ICU admission
Prazo: Day 1 of index ICU admission
|
CSL
|
Day 1 of index ICU admission
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Diretor de estudo: Hideaki Nonaka, Dr, The University of Queensland
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2025/PR011848
- INN2024-16 (Número de outro subsídio/financiamento: The Prince Charles Hospital Foundation (The Common Good))
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Prazo de Compartilhamento de IPD
Critérios de acesso de compartilhamento IPD
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CIF
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .